UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000028623
Receipt No. R000032595
Scientific Title Study on the interaction between barley beta-glucan and pharmaceutical products
Date of disclosure of the study information 2017/08/10
Last modified on 2018/03/30

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Study on the interaction between barley beta-glucan and pharmaceutical products
Acronym Study on the interaction between barley beta-glucan and pharmaceutical products
Scientific Title Study on the interaction between barley beta-glucan and pharmaceutical products
Scientific Title:Acronym Study on the interaction between barley beta-glucan and pharmaceutical products
Region
Japan

Condition
Condition Type 2 diabetes
Classification by specialty
Medicine in general
Classification by malignancy Others
Genomic information YES

Objectives
Narrative objectives1 Evaluate whether barley improves glycemic control of diabetic patients taking alpha-GI or metfolmin and reduces the risk of arteriosclerosis via incretins or inflammatory cytokines. The subjects shall be those who have (a) not received drug therapy, (b) taken alpha-GI (acarbose) and (c) taken metformin.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes Blood glucose (0, 30, 60, 90, 120 min)
Key secondary outcomes CGM Data
Insulin (0, 30, 60, 90, 120 min)
Inflammation related factor (0, 120 min)
Incretin (0, 30, 60, 120 min)
Feeding hormone (0, 30, 60, 120 min)

Safety data:
Weight, BMI
Blood pressure measurement
General biochemical test
Blood cell test

Questionnaire:
Advance questionnaire
Questionnaire(Test day)
Diet survey form

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control No treatment
Stratification NO
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 3
Purpose of intervention Treatment
Type of intervention
Food
Interventions/Control_1 Diet and exercise therapy group

The first day(D0), doctor's hearing, glucose tolerance test and installation of CGM are implemented. During a ingestion period, ingest 2 packs of white rice a day (D1 to D5), then ingest 2 packs of barley mixed rice a day (D6 to D12 or D13). Glucose tolerance tests are implemented again on the final day (D13 or D14). Test meals should be eaten as a staple foods of breakfast and supper. All subjects should record about their intake of meals and drugs.

Glucose tolerance test:
1) The day before tests
The day before the glucose tolerance test, refrain from excessive exercise, drinking alcohol and sitting up late. After 9 p.m., prohibit eating and drinking except water.

2) Test day
Measuring body weight, blood pressure and pulse in the hospital at the test day. Collecting fasting blood. Answer questionnaires of test day such as meal time of the previous day, sleeping time, exercise time of the previous day and so on.

3) Intake of test foods
After collecting fasting blood, intake glucose tolerance test meals. Test meals should be rice and energy-adjusted curry on the first day and barley mixed rice and energy-adjusted curry on the last day.

4) Blood collection
Blood is collected at 30, 60, 90, and 120 minutes after intake test meals.
Interventions/Control_2 Diet/exercise therapy + alpha-GI (acarbose) group
Except subjects, same as Interventions/Control 1.
Interventions/Control_3 Diet/exercise therapy + metformin group
Except subjects, same as Interventions/Control 1.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria (1) Type 2 diabetic patients who satisfy one of the following conditions.
A) Those who are treated with diet / exercise only.
B) In addition to diet / exercise therapy, those taking alpha-GI (acarbose).
C) In addition to diet / exercise therapy, those taking metformin.
Those taking acarbose or metformin should not change the dosage more than 60 days before D0.
(2) Persons whose HbA1c are 6.5 to 8.5% (when obtaining consent).
(3) Persons who are over 20 years old.
(4) Persons who obtained consent.
Key exclusion criteria (1) Serious ketosis, diabetic coma or precoma, patients with dialysis and type 1 diabetic patients.
(2) Patients with diseases or trauma such as serious infection, before and after surgery, cancer, etc.
(3) Those who are taking hypoglycemic drugs except the drugs listed in the selection criteria.
(4) Persons who merged gastrointestinal disorders affecting digestion / absorption.
(5) Persons who have a medical history of gastrointestinal resection.
(6) Persons who merged serious liver and kidney problems (as judged by a doctor).
(7) Persons who developed myocardial infarction / stroke within 180 days before D0.
(8) Persons who take systemic steroids (excluding local).
(9) Smokers.
(10) Persons who are drinking excessively (For example, 180 mL or more of sake per day, three or more big bottles of beer per day).
(11) Persons who have a history of hypersensitivity (food allergy etc.) to the test meals (barley, rice, wheat, milk ingredients, apples, beef, pork, soybeans and sesame).
(12) Persons who usually consume barley.
(13) Pregnant women or ladies who may be pregnant.
(14) Others who are judged inappropriate by the representative doctor.
Target sample size 30

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Takeshi Osonoi
Organization Nakakinen Clinic Medical corporation kensei-kai
Division name Director
Zip code
Address 745-5,Nakadai,Naka-city,Ibaraki-ken,311-0113,Japan
TEL 029-353-2800
Email t-osonoi@kensei-kai.com

Public contact
Name of contact person
1st name
Middle name
Last name Kensuke Ofuchi
Organization Nakakinen Clinic Medical corporation kensei-kai
Division name Department of clinical research
Zip code
Address 745-5,Nakadai,Naka-city,Ibaraki-ken,311-0113,Japan
TEL 029-353-2800
Homepage URL
Email k-ofuchi@kensei-kai.com

Sponsor
Institute Nakakinen Clinic Medical corporation kensei-kai
Institute
Department

Funding Source
Organization Hakubaku CO.,LTD.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor Faculty of Life and Environmental Sciences,University of Yamanashi
Name of secondary funder(s) None

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 医療法人 健清会 那珂記念クリニック(茨城県)

Other administrative information
Date of disclosure of the study information
2017 Year 08 Month 10 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 07 Month 25 Day
Date of IRB
Anticipated trial start date
2017 Year 08 Month 11 Day
Last follow-up date
2018 Year 03 Month 31 Day
Date of closure to data entry
2018 Year 03 Month 31 Day
Date trial data considered complete
2018 Year 03 Month 31 Day
Date analysis concluded
2018 Year 06 Month 30 Day

Other
Other related information

Management information
Registered date
2017 Year 08 Month 10 Day
Last modified on
2018 Year 03 Month 30 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032595

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.